A detailed history of Eagle Claw Capital Managment, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Eagle Claw Capital Managment, LLC holds 7,525 shares of VRTX stock, worth $3.57 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
7,525
Previous 7,525 -0.0%
Holding current value
$3.57 Million
Previous $3.06 Million 2.74%
% of portfolio
0.58%
Previous 0.65%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $12,005 - $14,373
-35 Reduced 0.46%
7,525 $3.06 Million
Q3 2023

Nov 07, 2023

BUY
$338.18 - $362.46 $40,581 - $43,495
120 Added 1.61%
7,560 $2.63 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $1.32 Million - $1.66 Million
7,440 New
7,440 $1.63 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Eagle Claw Capital Managment, LLC Portfolio

Follow Eagle Claw Capital Managment, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Claw Capital Managment, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Claw Capital Managment, LLC with notifications on news.